more Thank intended. you, to a we're much withdraw information enthusiasm products just generic disposal it's the believe provide Tom, We we possible able ROLVEDON. future Today, our we our like to outlook of and prudent learned we know guidance indomethacin until have hours issued ago, few When information. your approved and FDA I at as for guidance, today. has the now not share to a we as we as initially
single competitor status, all received can generics and we approved XXX other which CGT approved for days. a was they be as know no means Today,
that nor nor exclusivity entry risk afraid Assertio We has aware no are is What I been of well generic in is intellectual property background. always of not indomethacin protecting it this. the timing. not hiding launch known had their It and that from was this are we offer can
preparing So evident defend financials we we it. how and have is it, year. to example our we can defend been ready are One in of this for
X competitive this entered generics market authorized to and you As in many year generic. CAMBIA lost January for we in addition know, of exclusivity the of X
in brands months well X do the Normally, the not in to X LOE. first these following situations, do
an However, reduction prior result would outstanding of year-to-date, XX% volumes near retention year to the we've between many in customer end which suggest this, rates XX% of volume of the XX% competitive revenue, because revenues, when X% XX% like of retained of a and is prior the market and in to analogs year inventory.
the the refill This commercial programs due hub identification by for our were is in all to access in and with only and still this the at execution patient and being INDOCIN. our quickly analogs can outstanding commercial preparation X patient far are single early have competitor team similar And case, with our strategy refills case and something better rate. to market work. a a that we of high as our we An of programs and the LOE example covered the with We're CAMBIA. encourage utilizing do the support than resources insurers was that confident
want also product we in opioid. remarks but I the few products the comment OXAYDO performance. called as of business second a was his an which former details quarter to acquisition more a provide acquired with that prepared Zyla, abuse-deterrent things one is Egalet When I'll relate the to they core on and Assertio's came
marketing strong While put flows and or margins we cash it. a product contributor, small sales no carries support behind this because
a operations this it's for to both However, impact viewpoint, an from its been product financial in DEA supply challenge relative quota. and
the sales OXAYDO. and have FDA, to we the made this decision So product will discontinue of notified stop we've
of officially business. second the results. company have As is a This result, drag a opioid out half on will the decision our
$X.X And for year. we in sales half reported reference, OXAYDO second the million in last of
second turning our this for important this opioid as where as is think to or new from commonly is we've excited quarter, progress I'm very litigation, mark of in notable an dismissed us what cases point the in decision opioid we that referred were cases. NAS minority the to we significant made baby our history. I in a the announce
opioid aggregate, Now in dismissed without against of cases company been XX% all of just that a been the shy paying from filed the have we've penny. of
I think that is and our awarded. strategy volumes potential speaks and defense the about patients being this company's liability
I well continues mix our as strengths, the price, as quarter revenues discussed Symphony average trends last towards grew a TRX by peaks, shift monthly X% quarterly quarterly resulting net Health achieving selling SYMPAZAN average higher new measured so as count demand sequentially. -- the in and higher that
revenues first recover to $X.X represents from we are product, develop the period just back the strategic plans year and we about a challenges reasons to X.X% prior reported far with longer-term starting XXXX net optimism starting good for start over our for so have which million supply growth We're by are its half year. and the as OTREXUP to off for track the last experienced on product get over of Our We're Aquestive. potential.
quarter. Our up digits XX% and single last are low in volumes the year-over-year over
volumes. prices A who to market report contrast revenues as were revenues XX% year-over-year in sequentially we our as focused profitable net net downward primary our continues and up However, keep on share. they to XX% to bidding contract declining ASPs maintain competitor, direct
This just contracting small do we dollars one strategy then as are our smart, I market example of sales and described disciplined our of and everything what We're building business marketing the and overall. box is access allocate efficiently.
shift continued integration to now Spectrum the efforts of the ROLVEDON. trajectory Our launch of ensuring and
the to Paul. turn call over I will now
